Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

Clinical trial NCT06973629 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06973629
Sponsor: Brainstorm-Cell Therapeutics
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis

Start date: 2025-06-30
Primary completion: 2028-11-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.